Week Data News Today

Keep up the unhappy possibilities that impact IT resiliency -- from ransomware, to cloud outages, to natural disasters, to political upheaval -- and learn what to do about them.

This new data from the phase 2b trial on povorcitinib could lead to developments in the dermatology space for vitiligo patients.

Issuer: Immunic, Inc. / Key word(s): Study results Immunic Reports Positive Interim Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis 09.10.2023 / 22:01 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic Reports Positi...

– 24-Week Data from First Half of Patients Shows Improvements in Biomarker NfL, Consistent Throughout the Overall Progressive Multiple Sclerosis P...

Free Newsletter to InformationWeek Today Newsletter. Subscribe and get a snapshot of the issues affecting the IT industry. Youll hear about hot happenings and businesses that are leveraging technology to drive their operations forward.

Gilead to Present Data Across Viral Hepatitis and Liver Fibrosis at The Liver Meeting® 2022, Reinforcing Gilead as a Leader in Addressing Treatment Needs for People Living With Liver Disease

/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that it has submitted applications for a new indication to the U.S. Food and Drug Administration (FDA) and...

/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive top-line results from U-EXCEL, a Phase 3 induction study, showing upadacitinib (45 mg once daily)...

-Symposium on oral GnRH antagonists and personalized therapeutic approaches for women with uterine fibroids to be hosted Friday, December 10 at 1 p.m. CET- -52-Week Data from the Phase 3 PRIMROSE

AboutMyArea - Local news, events and much more.